title: Serum copeptin level can be a helpful biomarker in evaluation of myocardial perfusion scintigraphy results.
abstract: BACKGROUND
  Myocardial perfusion scintigraphy (MPS) is a well-established diagnostic tool. The sensitivity and specificity of single photon emission computed tomography (SPECT) MPS to detect significant coronary lesion were 86% and 74%, respectively. The aim of this study was to examine the role of serum copeptin in evaluation of MPS.
  
  
  METHODS
  Sixty-two consecutive patients underwent both SPECT MPS using 99mTc-sestamibi and transthoracic echocardiography were enrolled prospectively. Age, gender, height, weight, presence of cardiovascular risk factors were recorded. Exercise treadmill test (ETT) with modified Bruce protocol was used to induce coronary ischemia during MPS. While performing MPS, blood samples for serum copeptin level were drawn three times at pre-exercise, at the peak of ETT, and 6 h after ETT, respectively. The patients were enrolled into three groups according to MPS results (normal, equivocal and ischemia).
  
  
  RESULTS
  The study included 62 patients (23 with normal, 20 with equivocal, 19 with ischemia on MPS). Pre-, peak-, and post-exercise B-type natriuretic peptide and troponin I values were similar across the groups (p > 0.05 for all comparisons). Serum copeptin values for pre- and peak-exercise were similar among all groups (p = 0.883 and p = 0.089). Post-exercise copeptin values of the normal and equivocal groups were similar (p = 0.661, z = -0.438) while that of the ischemia group was significantly higher than both the normal (p < 0.001) and equivocal group (p < 0.001).
  
  
  CONCLUSIONS
  Serum copeptin was found to be increasing significantly in case of ischemia on MPS. It may be used in differentiation of equivocal results from false positive results.
authors.affiliation: Bozok University, Faculty of Medicine, Department of Cardiology, Yozgat, TURKEY. huseyinede@gmail.com.
authors.forename: Hüseyin
authors.initials: H
authors.lastname: Ede
authors.forename: Seyhan
authors.initials: S
authors.lastname: Karaçavuş
authors.forename: Ayşe Yeşim
authors.initials: AY
authors.lastname: Göçmen
authors.forename: Barış
authors.initials: B
authors.lastname: Yaylak
authors.forename: Süleyman
authors.initials: S
authors.lastname: Akkaya
authors.forename: Burak
authors.initials: B
authors.lastname: Açıkgöz
authors.forename: Neslihan
authors.initials: N
authors.lastname: Çilek
authors.forename: Mahmut
authors.initials: M
authors.lastname: Kılıç
authors.forename: Ali Rıza
authors.initials: AR
authors.lastname: Erbay
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D015150:Echocardiography, Doppler; D005080:Exercise Test; D005260:Female; D006020:Glycopeptides / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000097:blood* / Q000000981:diagnostic imaging*; D055414:Myocardial Perfusion Imaging / Q000379:methods*; D020097:Natriuretic Peptide, Brain / Q000097:blood; D011237:Predictive Value of Tests; D011446:Prospective Studies; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D017256:Technetium Tc 99m Sestamibi; D015899:Tomography, Emission-Computed, Single-Photon; D019210:Troponin I / Q000097:blood; D015854:Up-Regulation
chemical_list: D015415:Biomarkers; D006020:Glycopeptides; D019275:Radiopharmaceuticals; D019210:Troponin I; C048197:copeptins; D020097:Natriuretic Peptide, Brain; D017256:Technetium Tc 99m Sestamibi
keywords: copeptin; coronary artery disease; ischemia; myocardial perfusion scintigraphy